It should be noted that increased content of TSPO has been observed in a wide variety of cancer, including brain cancers [37,38], breast cancers [39,40], prostate cancers [41], colon cancers [42,43] and hepatic carcinomas [44] and, therefore, it is a biomarker in therapeutic diagnosis [45,46]. This evidence concerns the gene TSPO and prostate cancer.